News | January 23, 2024
Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
NEIAFMR to be developed as the national hub for folk medicine
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Subscribe To Our Newsletter & Stay Updated
